Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.

Abstract

BACKGROUND:

Despite androgen deprivation therapy (ADT) remains the mainstay therapy for advanced prostate cancer (PCa), the patients have widely variable durations of response to ADT. Unfortunately, there is limited knowledge of pre-treatment prognostic factors for response to ADT. Recently, microRNA-21 (miR-21) has been reported to play an important role in development of castration resistance of CaP. However, little is known about the expression of miR-21 in advanced PCa biopsy tissues, and data on its potential predictive value in advanced PCa are completely lacking.

METHODS:

In this study, paraffin-embedded prostate carcinoma tissues obtained by needle biopsy from 85 advanced PCa patients were evaluated for the expression levels of miR-21 by quantitative real-time PCR (qRT-PCR). In situ hybridization (ISH) analysis was performed to further confirm the qRT-PCR results. Kaplan-Meier analysis and Cox proportional hazards regression models were performed to investigate the correlation between miR-21 expression and time to progression of advanced PCa patients.

RESULTS:

Compared with adjacent non-cancerous prostate tissues, the expression level of miR-21 was significantly increased in PCa tissues (PCa vs. non-cancerous prostate: 1.3273 ± 0.3207 vs. 0.9970 ± 0.2054, P < 0.001). By and large, in ISH analysis miR-21 was expressed at a higher level in tumor areas than in adjacent non-cancerous areas. Additionally, PCa patients with higher expression of miR-21 were significantly more likely to be of high Gleason score and high clinical stage (P < 0.05). There was no significant association between miR-21 expression and the initial prostate-specific antigen (PSA) level or age at diagnosis. Moreover, Kaplan-Meier survival analysis found that PCa patients with high miR-21 expression have shorter progression-free survival than those with low miR-21 expression. Furthermore, Multivariate Cox analysis revealed both miR-21 expression status (P = 0.040) and clinical stage (P = 0.042) were all independent predictive factor for progression-free survival for advanced PCa.

CONCLUSION:

These findings suggest for the first time that the up-regulation of miR-21 may serve as an independent predictor of progress-free survival in patients with advanced PCa. Prostate 76:986-993, 2016. © 2016 Wiley Periodicals, Inc.

• Authors: Yangbo Guan, You Wu, Yifei Liu, Jian Ni, Shaojun Nong
• Journal: The Prostate (Prostate) Vol. 76 Issue 11 Pg. 986-93 (08 2016) ISSN: 1097-0045 [Electronic] United States
• PMID: 27040772 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2016 Wiley Periodicals, Inc.

Chemical References

• MIRN21 microRNA, human
• MicroRNAs
• Prostate-Specific Antigen

Topics

• Aged
• Aged, 80 and over
• Biopsy, Needle
• Disease-Free Survival
• Gene Expression
• Humans
• In Situ Hybridization
• Male
• MicroRNAs (analysis, genetics)
• Neoplasm Grading
• Orchiectomy
• Proportional Hazards Models
• Prostate (chemistry, pathology)
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (chemistry, genetics, pathology)
• Prostatic Neoplasms, Castration-Resistant (genetics, pathology)
• Real-Time Polymerase Chain Reaction
• Treatment Outcome
• Up-Regulation